Hearscape
← Therapeutics
Details checkedStatus confirmedHistorical/discontinuedCheckedtrial

CGF166 by Novartis

Also known as: CGF166, Hath1 gene therapy, ATOH1 gene therapy

Novartis

Primary source
Company
Novartis
Program Type
Therapeutic
Modality
Gene Therapy
Stage
Phase 1/2
Status
Completed
Target Gene
ATOH1
Route / Mode
Intralabyrinthine infusion
Confidence
89%
Status Confidence
Status confirmed
Evidence Strength
Needs more support
Last Reviewed
2026-05-31
Geography
United States
Population
adult, bilateral, profound
Trial IDs
1
Mechanism

Adenoviral ATOH1 gene transfer was intended to induce supporting cells to become new sensory hair cells in severe hearing loss.

Indications
Hearing LossSensorineural Hearing Loss
Notes

Historically important first-wave inner-ear gene therapy; clinical proof-of-concept was limited, but CGF166 established the feasibility of human hair-cell-regeneration gene transfer studies.

Evidence & Sources
3 structured sources
company
Supports: canonicalName, company, mechanism, targetGene, indications
IDs: CGF166
Open
clinicaltrials
Supports: trialIds, stage, route, populationTags, geography
IDs: NCT02132130
Open
company
Supports: route, targetGene, notes
IDs: CGF166
Open
Key Events
2014-11-19
Novartis publicly described the CGF166 inner-ear regeneration trial
Clinical Trials (1)
NCT02132130
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2